Cubist Systematic Strategies LLC Takes $4.66 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Cubist Systematic Strategies LLC acquired approximately 209,939 shares of Kiniksa Pharmaceuticals, valued at around $4.66 million, during the first quarter.
• Insiders have sold a total of 558,403 shares of Kiniksa Pharmaceuticals stock, worth approximately $18 million, in the last ninety days.
• Kiniksa Pharmaceuticals reported a net margin of 0.90% and earnings of $0.23 per share, beating the consensus estimate by $0.05.

Cubist Systematic Strategies LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 209,939 shares of the company's stock, valued at approximately $4,663,000. Cubist Systematic Strategies LLC owned approximately 0.29% of Kiniksa Pharmaceuticals International at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Kiniksa Pharmaceuticals International by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after acquiring an additional 151,604 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Kiniksa Pharmaceuticals International by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after purchasing an additional 54,361 shares during the last quarter. Millennium Management LLC increased its position in shares of Kiniksa Pharmaceuticals International by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after purchasing an additional 263,146 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Kiniksa Pharmaceuticals International by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its position in shares of Kiniksa Pharmaceuticals International by 1.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock valued at $15,141,000 after purchasing an additional 10,209 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KNSA. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Finally, Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock traded down $0.75 during mid-day trading on Wednesday, reaching $36.11. 84,213 shares of the company traded hands, compared to its average volume of 666,220. The company has a market capitalization of $2.68 billion, a P/E ratio of 903.35 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $37.25. The company has a fifty day moving average price of $31.32 and a 200-day moving average price of $26.77.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 17,000 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the transaction, the chief accounting officer owned 33,041 shares of the company's stock, valued at $1,068,876.35. The trade was a 33.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the transaction, the director directly owned 12,546 shares of the company's stock, valued at $415,147.14. The trade was a 86.18% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 562,271 shares of company stock worth $18,716,309. 53.48% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.